@article{ATM25996,
author = {Masayuki Nakamura and Masaki Okamoto and Kiminori Fujimoto and Tomohiro Ebata and Masaki Tominaga and Takashi Nouno and Yoshiaki Zaizen and Shinjiro Kaieda and Tohru Tsuda and Tomotaka Kawayama and Tomoaki Hoshino},
title = {A retrospective study of the tolerability of nintedanib for severe idiopathic pulmonary fibrosis in the real world},
journal = {Annals of Translational Medicine},
volume = {7},
number = {12},
year = {2019},
keywords = {},
abstract = {Background: Nintedanib is a tyrosine kinase inhibitor that has been shown to suppress progression of idiopathic pulmonary fibrosis (IPF). The efficacy and tolerability of nintedanib for IPF has been previously proven in the INPULSIS® and INPULSIS-On® trials. The aim of our study was to clarify the tolerability of nintedanib in the real world for severe IPF patients who were unable to enter the INPULSIS® and INPULSIS-On® trials.
Methods: We retrospectively investigated medical records of 8 patients with severe IPF and 14 patients with non-severe IPF who had been treated with nintedanib. The criteria to define severe IPF were forced vital capacity (FVC) of },
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/25996}
}